Exhibit 10.36 LICENSE AGREEMENTLicense Agreement • November 15th, 2002 • Autoimmune Inc • Biological products, (no disgnostic substances) • Delaware
SUBLEASE By and Between AUTOIMMUNE INC., as Sublandlord, andSublease • March 23rd, 1998 • Autoimmune Inc • Biological products, (no disgnostic substances)
between AUTOIMMUNE INC. and COLLORAL LLCTrademark License Agreement • November 15th, 2002 • Autoimmune Inc • Biological products, (no disgnostic substances) • Delaware
EXHIBIT 10.26 PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24(B)-2. THE LOCATION OF THOSE OMITTED PORTIONS IS DENOTED BY BRACKETS. DEVELOPMENT AND...Development and License Agreement • March 31st, 1999 • Autoimmune Inc • Biological products, (no disgnostic substances) • New York
BACKGROUND ----------Lease • March 31st, 1999 • Autoimmune Inc • Biological products, (no disgnostic substances)
Exhibit 4.3 AMENDMENT NO 1 TO RIGHTS AGREEMENT This Amendment No. 1 (the "Amendment"), dated as of March 20, 2001 is made by and between AutoImmune Inc., a Delaware corporation (the "Company"), and Computershare Trust Company, Inc. (formerly, American...Rights Agreement • March 23rd, 2001 • Autoimmune Inc • Biological products, (no disgnostic substances)
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24(B)-2. THE LOCATION OF THOSE OMITTED PORTIONS IS DENOTED BY BRACKETS.Research and Development Agreement • May 15th, 2000 • Autoimmune Inc • Biological products, (no disgnostic substances)
C) The Master Lease provides, inter alia that Tenant may not enter into ----- ---- any sublease without Landlord's prior written approval;Consent to Sublease • March 23rd, 1998 • Autoimmune Inc • Biological products, (no disgnostic substances)
AGREEMENT ---------Sublease Termination Agreement • March 31st, 1999 • Autoimmune Inc • Biological products, (no disgnostic substances)
EXHIBIT 10.22 THIRD AMENDMENT TO LEASE ------------------------ Amendment dated as of October 23, 1996 by and between Ledgemont Realty Trust u/d/t dated December 12, 1984 ("Landlord") and AutoImmune, Inc., a Delaware corporation ("Tenant"). A....Lease • March 23rd, 1998 • Autoimmune Inc • Biological products, (no disgnostic substances)
Exhibit 10.29 Effective as of January 3, 2000 Robert C. Bishop, Ph.D. 47 Carisbrooke Road Wellesley, MA 02481 Dear Bob: This will confirm our agreement pursuant to which you will act as a consultant to us ("AutoImmune"). As a consultant, you will...Consulting Agreement • March 30th, 2000 • Autoimmune Inc • Biological products, (no disgnostic substances)
As a consultant, you will provide senior management services to AutoImmune. Your services will include technology licensing; assistance in the preparation of press releases; assistance in the preparation of AutoImmune's filings with the Securities and Exchange Commission; assistance in the preparation of AutoImmune's proxy statement and annual report to stockholders; supervision of persons responsible for AutoImmune's financial statements; and assistance to AutoImmune's Board of Directors with respect to strategic planning and initiatives.
SUPPLY AND LICENSE AGREEMENT (INTERNATIONAL TERRITORIES)Supply and License Agreement • May 14th, 2007 • Autoimmune Inc • Biological products, (no disgnostic substances) • Utah
This Agreement is made effective as of April 9, 2007 by and between Colloral LLC, a Delaware limited liability company (“Colloral”), and Futurebiotics, LLC, a New York limited liability company (“Futurebiotics, LLC”).
DEVELOPMENT AND LICENSE AGREEMENT between AUTOIMMUNE INC. and RYCOR TECHNOLOGY INVESTMENTS CORP. dated as of August 1, 2000Development and License Agreement • June 19th, 2003 • Autoimmune Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS DEVELOPMENT AND LICENSE AGREEMENT dated as of August 1, 2000 (the “Agreement”) is made between AUTOIMMUNE INC., a Delaware corporation (“AutoImmune”), and RYCOR TECHNOLOGY INVESTMENTS CORP., a corporation under the laws of the Province of Alberta, Canada (“Rycor”).
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24(B)-2. THE LOCATION OF THOSE OMITTED PORTIONS IS DENOTED BY BRACKETS.Agreement for Assignment of Patent Rights • May 15th, 2000 • Autoimmune Inc • Biological products, (no disgnostic substances) • Delaware
SECOND AMENDMENT TO SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • March 25th, 2009 • Autoimmune Inc • Biological products, (no disgnostic substances)
THIS SECOND AMENDMENT is made as of this 15th day of January, 2009 by and between Colloral LLC and Futurebiotics, LLC and amends the Supply and License Agreement between the parties dated effective as of January 10, 2007, as amended. Capitalized terms used but not defined herein are used with the meanings set forth for those terms in the Supply and License Agreement.
Diane M. McClintockProfessional Services • August 24th, 2005 • Autoimmune Inc • Biological products, (no disgnostic substances)
AMENDMENT TO THE RESEARCH AND DEVELOPMENT AGREEMENT BETWEEN THE BRIGHAM AND WOMEN’S HOSPITAL, INC. AND AUTOIMMUNE, INC. (A5732)Research and Development Agreement • November 13th, 2003 • Autoimmune Inc • Biological products, (no disgnostic substances)
This Amendment to the Research and Development Agreement (“Amendment”) between The Brigham and Women’s Hospital, Inc. (“BWH”) and AutoImmune, Inc. (“Company”) is effective July 1, 2003. The BWH and the Company are parties to a Research and Development Agreement effective September 9, 1988, as amended and restated on July 1, 1992, April 14, 1995, July 1, 2000, July 1, 2001 and July 1, 2002 (“Agreement”), pursuant to which the BWH agreed to conduct certain scientific research in consideration of the payment of certain fees by the Company.
CLARIFICATION AND AMENDMENT OF BIOMS LICENSE AGREEMENTBioms License Agreement • March 21st, 2008 • Autoimmune Inc • Biological products, (no disgnostic substances)
WHEREAS AutoImmune and BioMS entered into a Development and License Agreement dated August 1, 2000 (the “BioMS License”) addressing the grant of license to certain Patent Rights in the Field, specifically the administration of native myelin basic protein (MBP) peptides by injection to non-mucosal sites for the treatment of Multiple Sclerosis;
FIRST AMENDMENT TO LIMITED LIABILITY COMPANY OPERATING AGREEMENT OF COLLORAL LLCLimited Liability Company Operating Agreement • August 31st, 2005 • Autoimmune Inc • Biological products, (no disgnostic substances)
This Agreement (“Amendment”), dated as of August 29, 2005, is made by and between AutoImmune Inc. and Deseret Laboratories, Inc. and amends the Limited Liability Company Operating Agreement of Colloral LLC dated as of August 19, 2002 between AutoImmune and Deseret (the “Operating Agreement”).
SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • May 14th, 2007 • Autoimmune Inc • Biological products, (no disgnostic substances) • Utah
This Agreement is made effective as of January 10, 2007 by and between Colloral LLC, a Delaware limited liability company (“Colloral”), and Futurebiotics, LLC, a New York limited liability company (“Futurebiotics, LLC”).
SUPPLY AND LICENSE AGREEMENTSupply and License Agreement • November 13th, 2007 • Autoimmune Inc • Biological products, (no disgnostic substances) • Utah
This Agreement is made effective as of August 20, 2007 by and among Colloral LLC, a Delaware limited liability company (“Colloral”), Bronson Laboratories, LLC a New York limited liability company, Futurebiotics, LLC, a New York limited liability company, and Jenasol LLC, a New York limited liability company.
